A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients

Alimentary Pharmacology and Therapeutics

Volumn 20, Issue 6, 2004, Pages 623-628

  Harrison, S A ^a   Fincke, C ^a   Helinski, D ^a   Torgerson, S ^a   Hayashi, P ^a  

^a BROOKE ARMY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GLUCOSE; HEMOGLOBIN A1C; LIPID; LIVER ENZYME; TETRAHYDROLIPSTATIN;

ADJUVANT THERAPY; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIET THERAPY; DRUG EFFICACY; EXERCISE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN TISSUE; LIPID BLOOD LEVEL; LIVER BIOPSY; LIVER FIBROSIS; MALE; NONALCOHOLIC FATTY LIVER; OBESITY; PATIENT COUNSELING; PILOT STUDY; PRIORITY JOURNAL; STEATOSIS; WEIGHT REDUCTION;

AGED; ANTI-OBESITY AGENTS; FATTY LIVER; FEMALE; HUMANS; LACTONES; MALE; MIDDLE AGED; OBESITY; WEIGHT LOSS;

EID: 4644305945     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.02153.x     Document Type: Article

References (21)

1. Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among U.S. adults, 1999-2000. JAMA 2002; 288: 1723-7.
2. Boyle JP, Honetcutt AA, Narayan KM, et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care 2002; 24: 1936-40.
3. Youssef WI, McCullough AJ. Steatohepatitis in obese individuals. Best Prac Res Clinic Castro 2002; 16: 733-47.
4. Harrison SA, Kadakia S, Lang KA, et al. Nonalcoholic Steatohepatitis: what we know in the new millennium. Am J Gastroenterol 2002; 97: 2714-24.
5. Bugianesi E, Leone N, Vanni G, et al. Expanding the natural history of nonalcoholic Steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastro 2002; 123: 134-40.
6. Shimada M, Hashimoto E, Tania M, et al. Hepatocellular carcinoma in patients with non-alcoholic Steatohepatitis. J Hepatol 2002; 37: 154-60.
7. Ong JP, Younossi ZM. Is hepatocellular carcinoma part of the natural history of nonalcoholic Steatohepatitis? Gastroenterology 2002; 123: 375-8.
8. Charlton M, Kasparova P, Weston S, et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29: 664-9.
9. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-31.
10. Anderson T, Gludd C, Franzmann MD, et al. Hepatic effects of dietary weight loss in morbidly obese patients. J Hepatol 1991; 12: 224-9.
11. Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990; 99: 1408-13.
12. Drenick EJ, Simmons F, Murphy J. Effect on hepatic morphology of treatment of obesity by fasting, reducing diets, and small bowel bypass. N Eng J Med 1970; 282: 829-34.
13. Ueno T, Sagawara H, Sujaka K, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997; 27: 103-7.
14. Rozental P, Biava C, Spencer H, et al. Liver morphology and function tests in obesity and during total starvation. Am J Dig Dis 1967; 12: 198-208.
15. Heck AM, Yanovski JA, Calis KA. Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy 2000; 20: 270-9.
16. Wang RT, Koretz RL, Yee HF. Is weight reduction an effective therapy for nonalcoholic fatty liver? A systematic review. Am J Med 2003; 115: 554-9.
17. Brunt EM, Janney CG, De Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histologic lesions. Am J Gastroenterol 1999; 2467-71.
18. Harrison SA, Ramrakhiani S, Brunt EM, et al. Orlistat in the treatment of NASH: a case series. Am J Gastroenterol 2003; 98: 926-30.
19. Promrat K, Lutchman G, Uwaifo GI, et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004; 39: 188-96.
20. Harrison SA, Torgerson S, Ward J, et al. Vitamin E and vitamin C treatment improves flbrosis in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003; 98: 2485-90.
21. Lindor KD, Kowdley KV, Heathcote EJ, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology 2004; 39: 770-8.